Equities analysts predict that Geron Co. (NASDAQ:GERN) will announce sales of $140,000.00 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Geron’s earnings. The highest sales estimate is $180,000.00 and the lowest is $100,000.00. Geron reported sales of $170,000.00 during the same quarter last year, which indicates a negative year-over-year growth rate of 17.6%. The firm is expected to announce its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Geron will report full-year sales of $450,000.00 for the current year, with estimates ranging from $400,000.00 to $510,000.00. For the next year, analysts expect that the business will report sales of $20.49 million, with estimates ranging from $400,000.00 to $40.58 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Geron.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Geron had a negative return on equity of 22.33% and a negative net margin of 5,328.80%. The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.20 million.

GERN has been the subject of a number of research analyst reports. HC Wainwright started coverage on Geron in a report on Tuesday, September 3rd. They set a “buy” rating and a $4.00 price target for the company. ValuEngine upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. BidaskClub upgraded shares of Geron from a “sell” rating to a “hold” rating in a research note on Saturday, August 17th. B. Riley boosted their target price on shares of Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a research report on Friday, June 28th. Finally, Cantor Fitzgerald began coverage on shares of Geron in a research note on Thursday, August 15th. They set an “overweight” rating and a $4.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $3.55.

GERN traded up $0.02 during midday trading on Friday, reaching $1.49. The company’s stock had a trading volume of 1,664,587 shares, compared to its average volume of 2,351,870. The company has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $1.52. The stock has a market cap of $269.45 million, a P/E ratio of -9.31 and a beta of 2.57. Geron has a twelve month low of $0.95 and a twelve month high of $6.99.

A number of hedge funds have recently added to or reduced their stakes in GERN. Jane Street Group LLC bought a new position in Geron during the second quarter valued at about $71,000. Vanguard Group Inc. grew its stake in Geron by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 9,644,900 shares of the biopharmaceutical company’s stock worth $13,599,000 after buying an additional 141,384 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Geron by 482.4% in the second quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 24,684 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of Geron during the second quarter valued at $252,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Geron by 11.0% during the second quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 79,827 shares during the period. 31.16% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Article: Bollinger Bands

Get a free copy of the Zacks research report on Geron (GERN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.